Key Highlights

  • HCW Biologics showcased preclinical and human data for its IL-15 fusion and TGF-β trap platform.
  • The technology underpins next-generation TRBC-based checkpoint inhibitors and T-cell engagers HCW11-040 and HCW11-018b.
  • Both programs are in IND-enabling development.
  • Clinical trial starts are projected for 2027; shares closed up 17% at $3.17.

A Platform Update Spanning Preclinical and Human Data

HCW Biologics Inc. (NASDAQ:HCWB) presented both preclinical and human data supporting its IL-15 fusion and TGF-β trap platform. IL-15 is a cytokine known for its role in stimulating and sustaining immune cells such as natural killer cells and CD8+ T cells, while a TGF-β trap is designed to neutralize transforming growth factor-beta, a signaling protein that tumors often use to suppress the surrounding immune response. Combining the two mechanisms in a single molecule is intended to simultaneously boost immune cell activity and remove one of the tumor's key defenses against that activity.

Application in Next-Generation Programs

This platform technology is integrated into the company's next-generation TRBC-based checkpoint inhibitors and T-cell engagers, HCW11-040 and HCW11-018b. TRBC-based constructs are engineered around T-cell receptor Beta constant region targeting, an approach being explored as a way to direct T-cell engaging therapies with greater specificity. Both HCW11-040 and HCW11-018b are currently in IND-enabling development, the preclinical stage in which companies generate the safety and Manufacturing data required to support an Investigational New Drug application before human dosing can begin.

Timeline to the Clinic

HCW Biologics (NASDAQ:HCWB) has projected clinical trial starts for both programs in 2027. That timeline places the current data disclosure roughly a year or more ahead of first-in-human dosing, meaning today's update is a platform and preclinical validation step rather than a clinical efficacy or safety readout.

Market Reaction

Shares of HCW Biologics (NASDAQ:HCWB) closed up 17% at $3.17, reflecting investor interest in the breadth of data supporting the underlying platform ahead of the programs' eventual entry into human trials.

What platform did HCW Biologics present data on?

HCW Biologics (NASDAQ:HCWB) presented preclinical and human data for its IL-15 fusion and TGF-β trap platform.

Which programs use this platform?

The platform is integrated into next-generation TRBC-based checkpoint inhibitors and T-cell engagers HCW11-040 and HCW11-018b.

When are Clinical Trials expected to start for these programs?

Both programs are in IND-enabling development, with clinical trial starts projected for 2027.